Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKesson
Covington
Cerilliant
Deloitte
UBS
US Department of Justice
Accenture
US Army

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,025,290

« Back to Dashboard

Which drugs does patent 7,025,290 protect, and when does it expire?

Patent 7,025,290 protects VARITHENA and is included in one NDA.

This patent has seventy patent family members in thirty-four countries.
Summary for Patent: 7,025,290
Title:Generation of therapeutic microfoam
Abstract: Improved therapeutic sclerosing microfoams are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.
Inventor(s): Osman; Tariq (London, GB), Harman; Anthony David (Checkendon, GB), Boorman; Timothy David (Frinton on Sea, GB), Flynn; Sheila Bronwen (Nr. Stevenage, GB), Wright; David Dakin Iorwerth (High Wycombe, GB)
Assignee: BTG International Limited (London, GB)
Application Number:10/300,758
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Device; Delivery;

Drugs Protected by US Patent 7,025,290

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,025,290

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9912356May 26, 1999
United KingdomPCT/GB00/02045May 26, 2000

Non-Orange Book US Patents Family Members for Patent 7,025,290

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,357,336 Generation of therapeutic microfoam ➤ Try a Free Trial
6,572,873 Generation of therapeutic microfoam ➤ Try a Free Trial
8,091,801 Generation of therapeutic microfoam ➤ Try a Free Trial
7,604,185 Generation of therapeutic microfoam ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,025,290

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 025530 ➤ Try a Free Trial
Argentina 027175 ➤ Try a Free Trial
Argentina 089412 ➤ Try a Free Trial
Austria 313317 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKesson
Citi
Argus Health
AstraZeneca
Cipla
Healthtrust
Express Scripts
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.